What You Need to Know About Roche AG's Breast Cancer Drug Perjeta
Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates.
Roche AG (RHHBY) saw major success in the "Aphinity" clinical trial of its breast cancer drug Perjeta. Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates. Such success could spell trouble for competitor Puma Biotechnology's (PBYI) - Get Report unapproved breast cancer drug neratinib.
READ THE FULL STORY HERE: Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win
This article was written by a staff member of TheStreet.
